Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT)

Arcturus Therapeutics Holdings Inc., often referred to as Arcturus, operates in the biotechnology industry, specifically in the mRNA therapeutics and vaccines segment. The company's primary focus is on the development of infectious disease vaccines and therapeutics for liver and respiratory rare diseases. Its full name is Arcturus Therapeutics Holdings Inc., and its stock symbol is ARCT.

Arcturus' main business activities revolve around the development of mRNA-based vaccines and therapeutics. These products are designed to treat and prevent various diseases, including COVID-19, influenza, and rare genetic disorders. The company's operations span across different countries and regions, as it works towards providing innovative solutions to global health challenges.

The company generates revenue primarily through the development and commercialization of its mRNA-based vaccines and therapeutics. Arcturus' revenue is derived from various sources, including grants, collaborations, and licensing agreements with other companies.

Arcturus' vaccines franchise is dedicated to the development of mRNA-based vaccines for infectious diseases. This includes COVID-19, influenza, and other respiratory viruses. Arcturus' vaccines are designed to stimulate the immune system to produce antibodies and T-cells that can recognize and fight against specific pathogens. The company's mRNA-based vaccines have shown promising results in clinical trials, with its COVID-19 vaccine, ARCT-154, receiving marketing authorization approval in Japan in November 2023.

In addition to its vaccines franchise, Arcturus also has a rare disease pipeline. This pipeline is focused on the development of mRNA-based therapeutics for rare genetic disorders, including ornithine transcarbamylase (OTC) deficiency and cystic fibrosis. The company's rare disease pipeline includes several clinical-stage programs, such as ARCT-810, which is currently in Phase 2 clinical trials for OTC deficiency.

Arcturus' LUNAR and STARR technology platforms are proprietary systems that enable the safe and effective delivery of mRNA therapeutics to target cells. The LUNAR platform is a multi-component drug delivery system that incorporates a mixture of novel biodegradable lipids. It is designed to address technical challenges facing the delivery of nucleic acid medicines into cells. On the other hand, the STARR platform is a proprietary self-amplifying mRNA technology platform that enables the production of sustained protein expression at lower dose levels. It is designed to trigger rapid and prolonged antigen expression within host cells, affording individuals protective immunity against infectious pathogens.

Arcturus' competitive advantages include its proprietary LUNAR and STARR technology platforms. These platforms enable the safe and effective delivery of mRNA therapeutics to target cells. Additionally, the company's mRNA-based vaccines and therapeutics have shown promising results in clinical trials. Arcturus' collaborations with other companies, such as CSL Seqirus and Meiji, have also contributed to its competitive advantages. These partnerships have allowed the company to leverage the expertise and resources of its partners to accelerate the development of its mRNA-based vaccines and therapeutics.

Arcturus' customers include various government agencies, non-profit organizations, and private companies. These customers are primarily focused on the development and commercialization of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders.

Arcturus' product portfolio includes several brand names and trade names. These include its LUNAR and STARR technology platforms, as well as its various mRNA-based vaccines and therapeutics. However, specific product names are not mentioned in the provided document.